Steven J de Jongh1, Josephina P M Vrouwe2, Floris J Voskuil3, Iris Schmidt1, Jessie Westerhof1, Jan J Koornstra1, Marieke L de Kam2, Arend Karrenbeld4, James C H Hardwick5, Dominic J Robinson6, Jacobus Burggraaf2, Ingrid M C Kamerling2, Wouter B Nagengast7. 1. Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands. 2. Centre for Human Drug Research, Leiden, The Netherlands. 3. Department of Oral and Maxillofacial Surgery, University Medical Center Groningen, Groningen, The Netherlands. 4. Department of Pathology, University Medical Center Groningen, Groningen, The Netherlands. 5. Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands; and. 6. Center for Optical Diagnostics and Therapy, Department of Otorhinolaryngology and Head and Neck Surgery, Erasmus MC Cancer Institute, Rotterdam, The Netherlands. 7. Department of Gastroenterology and Hepatology, University Medical Center Groningen, Groningen, The Netherlands w.b.nagengast@umcg.nl.
Abstract
Fluorescence molecular endoscopy (FME) is an emerging technique that has the potential to improve the 22% colorectal polyp detection miss-rate. We determined the optimal dose-to-imaging interval and safety of FME using EMI-137, a c-Met-targeted fluorescent peptide, in a population at high risk for colorectal cancer. Methods: We performed in vivo FME and quantification of fluorescence by multidiameter single-fiber reflectance/single-fiber fluorescence spectroscopy in 15 patients with a dysplastic colorectal adenoma. EMI-137 was intravenously administered (0.13 mg/kg) at a 1-, 2- or 3-h dose-to-imaging interval (n = 3 patients per cohort). Two cohorts were expanded to 6 patients on the basis of target-to-background ratios. Fluorescence was correlated to histopathology and c-Met expression. EMI-137 binding specificity was assessed by fluorescence microscopy and in vitro experiments. Results: FME using EMI-137 appeared to be safe and well tolerated. All dose-to-imaging intervals showed significantly higher fluorescence in the colorectal lesions than in surrounding tissue, with a target-to-background ratio of 1.53, 1.66, and 1.74 for the 1-, 2-, and 3-h cohorts, respectively, and a mean intrinsic fluorescence of 0.035 vs. 0.023 mm-1 (P < 0.0003), 0.034 vs. 0.021 mm-1 (P < 0.0001), and 0.033 vs. 0.019 mm-1 (P < 0.0001), respectively. Fluorescence correlated with histopathology on a macroscopic and microscopic level, with significant c-Met overexpression in dysplastic mucosa. In vitro, a dose-dependent specific binding was confirmed. Conclusion: FME using EMI-137 appeared to be safe and feasible within a 1- to 3-h dose-to-imaging interval. No clinically significant differences were observed among the cohorts, although a 1-h dose-to-imaging interval was preferred from a clinical perspective. Future studies will investigate EMI-137 for improved colorectal polyp detection during screening colonoscopies.
Fluorescence molecular endoscopy (FME) is an emerging technique that has the potential to improve the 22% colorectal polyp detection miss-rate. We determined the optimal dose-to-imaging interval and safety of FME using EMI-137, a c-Met-targeted fluorescent peptide, in a population at high risk for colorectal cancer. Methods: We performed in vivo FME and quantification of fluorescence by multidiameter single-fiber reflectance/single-fiber fluorescence spectroscopy in 15 patients with a dysplastic colorectal adenoma. EMI-137 was intravenously administered (0.13 mg/kg) at a 1-, 2- or 3-h dose-to-imaging interval (n = 3 patients per cohort). Two cohorts were expanded to 6 patients on the basis of target-to-background ratios. Fluorescence was correlated to histopathology and c-Met expression. EMI-137 binding specificity was assessed by fluorescence microscopy and in vitro experiments. Results: FME using EMI-137 appeared to be safe and well tolerated. All dose-to-imaging intervals showed significantly higher fluorescence in the colorectal lesions than in surrounding tissue, with a target-to-background ratio of 1.53, 1.66, and 1.74 for the 1-, 2-, and 3-h cohorts, respectively, and a mean intrinsic fluorescence of 0.035 vs. 0.023 mm-1 (P < 0.0003), 0.034 vs. 0.021 mm-1 (P < 0.0001), and 0.033 vs. 0.019 mm-1 (P < 0.0001), respectively. Fluorescence correlated with histopathology on a macroscopic and microscopic level, with significant c-Met overexpression in dysplastic mucosa. In vitro, a dose-dependent specific binding was confirmed. Conclusion: FME using EMI-137 appeared to be safe and feasible within a 1- to 3-h dose-to-imaging interval. No clinically significant differences were observed among the cohorts, although a 1-h dose-to-imaging interval was preferred from a clinical perspective. Future studies will investigate EMI-137 for improved colorectal polyp detection during screening colonoscopies.
Authors: Judith A Stibbe; Petra Hoogland; Friso B Achterberg; Derek R Holman; Raoul S Sojwal; Jacobus Burggraaf; Alexander L Vahrmeijer; Wouter B Nagengast; Stephan Rogalla Journal: Mol Imaging Biol Date: 2022-06-28 Impact factor: 3.488
Authors: Grant Halliday; Ross J Porter; Catherine J Black; Mark J Arends; Shahida Din Journal: World J Gastroenterol Date: 2022-04-07 Impact factor: 5.374
Authors: Tessa Buckle; Albertus W Hensbergen; Danny M van Willigen; Frank Bosse; Kevin Bauwens; Rob C M Pelger; Fijs W B van Leeuwen Journal: EJNMMI Res Date: 2021-05-29 Impact factor: 3.138
Authors: Hielke M de Vries; Elise Bekers; Matthias N van Oosterom; M Baris Karakullukcu; Henk G van; Fijs W B van Leeuwen; Tessa Buckle; Oscar R Brouwer Journal: J Nucl Med Date: 2021-05-14 Impact factor: 11.082
Authors: Daan Linders; Marion Deken; Maxime van der Valk; Willemieke Tummers; Shadhvi Bhairosingh; Dennis Schaap; Gesina van Lijnschoten; Elham Zonoobi; Peter Kuppen; Cornelis van de Velde; Alexander Vahrmeijer; Arantza Farina Sarasqueta; Cornelis Sier; Denise Hilling Journal: Diagnostics (Basel) Date: 2021-03-14
Authors: Alba Alfonso-Garcia; Stephanie A Cevallos; Jee-Yon Lee; Cai Li; Julien Bec; Andreas J Bäumler; Laura Marcu Journal: Molecules Date: 2022-02-15 Impact factor: 4.411
Authors: Pascal K C Jonker; Madelon J H Metman; Luc H J Sondorp; Mark S Sywak; Anthony J Gill; Liesbeth Jansen; Thera P Links; Paul J van Diest; Tessa M van Ginhoven; Clemens W G M Löwik; Anh H Nguyen; Robert P Coppes; Dominic J Robinson; Gooitzen M van Dam; Bettien M van Hemel; Rudolf S N Fehrmann; Schelto Kruijff Journal: Eur J Nucl Med Mol Imaging Date: 2022-04-07 Impact factor: 10.057